Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Tema Oncology ETF(CANC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CANC
10/28/2026: CANC (2-star) is currently NOT-A-BUY. Pass it for now.
The Tema Oncology ETF (CANC) provides targeted, actively managed exposure to companies leading the fight against cancer. By concentrating on oncology research and innovation, the fund avoids the dilution of broad healthcare indices, making it a potential alpha-generator for growth-focused investors. However, it carries high volatility, concentration risk, and higher management fees compared to passive biotech alternatives. It is best suited for risk-tolerant, long-term investors who understand the binary nature of clinical trials and the cyclical nature of biotech valuations. Investors should monitor FDA regulatory changes, M&A trends, and the fund's expense ratio relative to its performance over time.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets companies with high growth potential in the oncology innovation space. |
| Momentum investor | Strong fit while signal remains positive | Biotech stocks in this fund can exhibit strong momentum based on clinical trial success and M&A speculation. |
| Value investor | Weak fit | Many oncology-focused companies are in early stages and do not trade based on traditional value metrics like P/E ratios. |
| Dividend/Income investor | Weak fit | Most companies in this space reinvest capital into research and do not pay significant dividends. |
| Low-risk investor | Weak fit | The volatility inherent in biotechnology and concentrated thematic portfolios is unsuitable for low-risk profiles. |
Investor Profile
Ideal Investor Profile
The ideal investor is an aggressive growth-oriented individual or institutional investor with a high risk tolerance and a multi-year time horizon.
Suitability
CANC is best suited for long-term investors seeking thematic exposure rather than active traders who might be deterred by lower liquidity.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Biotech stocks are prone to significant price swings based on clinical and regulatory outcomes. |
| Market risk | Medium / high | The fund is susceptible to general market corrections and healthcare sector downturns. |
| Concentration | High | By focusing on a single therapeutic area (oncology), the fund lacks the diversification of a broader healthcare portfolio. |
| Tracking/expense | Medium | The active management fee is higher than passive index-tracking alternatives. |
| Liquidity | Medium | Low trading volumes can lead to slippage when entering or exiting large positions. |
| Business/sector quality | High | The success of the underlying companies is heavily dependent on R&D success and FDA approval paths. |
Risk Analysis
Volatility
CANC exhibits high historical volatility consistent with early-stage and clinical-stage biotechnology equities.
Market Risk
The fund is highly sensitive to biotechnology-specific sentiment and general market appetite for speculative growth.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Global Oncology & Biotechnology Equities | 98 | This exposure provides targeted access to the high-growth and high-risk segment of cancer treatment and diagnostics companies. |
| Cash/collateral | Cash and Cash Equivalents | 2 | This small liquidity buffer is held to manage daily flows and transaction settlements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 57.1% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.